Daré Bioscience (DARE) Q3 2024 earnings summary

Executive summary

• Secured over $20 million in non-dilutive funding in the last 30 days, including a $10.7 million Gates Foundation grant and a $10 million ARPA-H award, supporting pipeline acceleration and clinical site expansion.

• Focused on advancing a broad portfolio of first-in-category women's health products, with late-stage candidates including Ovaprene, Sildenafil Cream, DARE-HPV, DARE-VVA1, and DARE-PTB1.

• Commercialization of XACIATO, the first FDA-approved product, is progressing with steady prescription growth and expanded access through Organon.

• Five product candidates are in advanced clinical development, with several others in earlier or preclinical stages.

• The company faces substantial doubt about its ability to continue as a going concern due to insufficient cash for the next 12 months.

Financial highlights

• General and administrative expenses for Q3 2024 were $2 million, a 24% decrease year-over-year.

• R&D expenses were $2.7 million in Q3 2024, down 60% year-over-year, mainly due to completion of the Phase 2b study for Sildenafil Cream.

• Net loss for Q3 2024 was $4.7 million, improved from $8.3 million in Q3 2023; nine-month net income was $1.5 million, driven by a $20.4 million royalty sale.

• Cash and cash equivalents at September 30, 2024 were $11.2 million, with working capital of $1.8 million.

• Total revenue for Q3 2024 was $41,691, down from $1.0 million in Q3 2023.

Outlook and guidance

• Anticipates meaningful milestones in 2025, including interim data from the Ovaprene pivotal study and potential phase III initiation for Sildenafil Cream, supported by recent grants and a $15 million equity line.

• Ovaprene Phase 3 study recruitment ongoing at over 10 U.S. sites, with additional sites expected to accelerate enrollment.

• Two successful Phase 3 studies required for Sildenafil Cream NDA, with each study estimated at $15 million in direct costs.

• Additional capital is required to fund operations and execute the current business strategy; management is actively pursuing various financing options.

• R&D expenses will focus on Ovaprene and Sildenafil Cream, with preclinical programs supported by grant funding.